Catalyst Pharmaceuticals shares face Nasdaq suspension as company moves to delist after merger

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRX

0.00
  • Catalyst Pharmaceuticals notified Nasdaq of its merger close, seeking removal of its common stock from the Nasdaq Capital Market.
  • Nasdaq was asked to keep the trading halt in place through July 15, 2026; the stock is set to be suspended July 16, 2026.
  • The company expects Nasdaq to file a Form 25 to delist and deregister the shares under Exchange Act Section 12(b).
  • Following Form 25 effectiveness, Catalyst plans to file a Form 15 to terminate registration under Section 12(g), suspending reporting under Sections 13 and 15(d).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-304984), on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.